INmune Bio (NASDAQ:INMB) Receives New Coverage from Analysts at Raymond James
Raymond James assumed coverage on shares of INmune Bio (NASDAQ:INMB – Free Report) in a research note published on Friday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $18.00 price objective on the stock. Separately, Scotiabank initiated coverage on INmune Bio in a research note on Thursday, August 22nd. They set […]
1 Oct 01:49 · The Cerbat Gem